Pfizer Eyes Flat Revenue as Pfe Stock Slips 5.2%
pfe stock has fallen 5.2% over the last month as Pfizer heads into Tuesday morning’s earnings report with Wall Street expecting revenue to be flat year on year. That sets up a narrow test for a company that rarely misses revenue estimates, but did post a significant miss on organic revenue last quarter.
Pfizer reported $17.56 billion in revenue last quarter, down 1.2% year on year, while still beating analysts’ top-line expectations. The strain now is on whether the next print can hold that pattern after revenue estimates were revised lower in a majority of the last 30 days.
Analysts Cut Estimates in 30 Days
Revenue estimates for Pfizer saw a majority of downward revisions over the last 30 days, leaving the consensus for flat year-on-year revenue this quarter. That is a step down from the 7.8% decline Pfizer posted in the same quarter last year, so the setup is less about growth and more about whether management can keep the top line from slipping again.
$26.38 is where Pfizer’s shares trade now, below the $29.00 average analyst price target. The gap leaves the market pricing in less than analysts do, even after the stock’s weak month relative to the sector.
Eli Lilly and Merck Set the Bar
55.5% revenue growth at Eli Lilly and 13.7% outperformance versus estimates gave the branded pharmaceuticals segment a much stronger benchmark than Pfizer faces this week. Merck added 4.9% revenue and beat estimates by 3%, then traded up 1%, while Eli Lilly rose 13.2% after its results.
6% was the average monthly gain for branded pharmaceuticals shares, which makes Pfizer’s 5.2% decline stand out even more. If the company merely matches the flat revenue forecast, it may stop the underperformance from widening; if it follows the peer pattern, the market will have a clearer reason to narrow the discount to the $29.00 target.
Tuesday Before the Bell
Tuesday before the bell is the moment that will settle whether Pfizer’s recent revenue revisions were cautious or still too optimistic. Traders looking for a cleaner read than last quarter’s organic revenue miss should focus on the top-line number first, because that is the one figure the market has already anchored on.
